Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the appearance of α-synuclein insoluble aggregates known as Lewy bodies. Neurodegeneration is accompanied by neuroinflammation mediated by cytokines and chemokines produced by the activated microglia. Several studies demonstrated that such an inflammatory process is an early event, and contributes to oxidative stress and mitochondrial dysfunctions. α-synuclein fibrillization and aggregation activate microglia and contribute to disease onset and progression. Mutations in different genes exacerbate the inflammatory phenotype in the monogenic compared to sporadic forms of PD. Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) with selected radiopharmaceuticals allow in vivo imaging of molecular modifications in the brain of living subjects. Several publications showed a reduction of dopaminergic terminals and dopamine (DA) content in the basal ganglia, starting from the early stages of the disease. Moreover, non-dopaminergic neuronal pathways are also affected, as shown by in vivo studies with serotonergic and glutamatergic radiotracers. The role played by the immune system during illness progression could be investigated with PET ligands that target the microglia/macrophage Translocator protein (TSPO) receptor. These agents have been used in PD patients and rodent models, although often without attempting correlations with other molecular or functional parameters. For example, neurodegeneration and brain plasticity can be monitored using the metabolic marker 2-Deoxy-2-[18F]fluoroglucose ([18F]-FDG), while oxidative stress can be probed using the copper-labeled diacetyl-bis(N-methyl-thiosemicarbazone) ([Cu]-ATSM) radioligand, whose striatal-specific binding ratio in PD patients seems to correlate with a disease rating scale and motor scores. Also, structural and functional modifications during disease progression may be evaluated by Magnetic Resonance Imaging (MRI), using different parameters as iron content or cerebral volume. In this review article, we propose an overview of in vivo clinical and non-clinical imaging research on neuroinflammation as an emerging marker of early PD. We also discuss how multimodal-imaging approaches could provide more insights into the role of the inflammatory process and related events in PD development.
Belloli, S., Morari, M., Murtaj, V., Valtorta, S., Moresco, R., & Gilardi, M. (2020). Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation. FRONTIERS IN AGING NEUROSCIENCE, 12.
|Citazione:||Belloli, S., Morari, M., Murtaj, V., Valtorta, S., Moresco, R., & Gilardi, M. (2020). Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation. FRONTIERS IN AGING NEUROSCIENCE, 12.|
|Tipo:||Articolo in rivista - Review Essay|
|Carattere della pubblicazione:||Scientifica|
|Presenza di un coautore afferente ad Istituzioni straniere:||No|
|Titolo:||Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation|
|Autori:||Belloli, S; Morari, M; Murtaj, V; Valtorta, S; Moresco, R; Gilardi, M|
MORESCO, ROSA MARIA (Penultimo)
GILARDI, MARIA CARLA (Ultimo)
|Data di pubblicazione:||2020|
|Rivista:||FRONTIERS IN AGING NEUROSCIENCE|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3389/fnagi.2020.00152|
|Appare nelle tipologie:||01 - Articolo su rivista|